{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:40:32Z","timestamp":1778712032512,"version":"3.51.4"},"reference-count":40,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:p>BACKGROUND. Adolescent obesity is a major public health problem. Treatment options in addition to behavioral therapy could include pharmacotherapy with sibutramine.<\/jats:p>\n               <jats:p>OBJECTIVES. Concerns regarding increases in blood pressure and heart rate after sibutramine treatment in some adult patients precipitated the present analysis, which evaluated the cardiovascular safety of sibutramine plus a behavioral therapy program in obese adolescents.<\/jats:p>\n               <jats:p>PATIENTS AND METHODS. With this 12-month, randomized, double-blind, placebo-controlled trial in 33 US clinics we studied 498 adolescents aged 12 to 16 years with multiethnic backgrounds and BMIs of 28.1 to 46.3 kg\/m2.<\/jats:p>\n               <jats:p>RESULTS. The subjects were randomly assigned to behavioral therapy plus 10 mg of sibutramine or behavioral therapy plus placebo daily. At the end point, there was a mean treatment group difference in BMI of 2.6 kg\/m2 in favor of sibutramine. Small mean decreases in blood pressure and pulse rate were seen in both sibutramine and placebo groups at the end point (systolic blood pressure: \u22122.1 vs \u22122.1 mmHg; diastolic blood pressure: \u22120.1 vs \u22121.1 mmHg; pulse rate: \u22120.2 vs \u22121.8 bpm). In both treatment groups, these reductions in vital signs were greater at the end point when BMI reduction was \u22655% compared with &amp;lt;5%.<\/jats:p>\n               <jats:p>CONCLUSIONS. Sibutramine may have some direct cardiovascular effects on obese adolescents. These cardiovascular effects may be balanced by a reduction in BMI, which, in adolescents, seems to be greater than that observed in adults.<\/jats:p>","DOI":"10.1542\/peds.2006-2137","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:53:29Z","timestamp":1182214409000},"page":"e147-e157","source":"Crossref","is-referenced-by-count":42,"title":["Cardiovascular Effects of Sibutramine in the Treatment of Obese Adolescents: Results of a Randomized, Double-Blind, Placebo-Controlled Study"],"prefix":"10.1542","volume":"120","author":[{"given":"Stephen R.","family":"Daniels","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Crow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Styne","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Sothern","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Louisiana State University Health Sciences and Pennington Research Centers, New Orleans, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Vargas-Rodriguez","sequence":"additional","affiliation":[{"name":"Comprehensive Weight Control Program, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Harris","sequence":"additional","affiliation":[{"name":"Chase Wellness Center, Virginia Beach, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Walch","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Jasinsky","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Cwik","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Hewkin","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Blakesley","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Sibutramine Adolescent Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2007,7,1]]},"reference":[{"key":"2021120901594179500_R1","doi-asserted-by":"crossref","unstructured":"Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960\u20131994. Int J Obes Relat Metab Disord.\u20081998;22:39\u201347","DOI":"10.1038\/sj.ijo.0800541"},{"key":"2021120901594179500_R2","doi-asserted-by":"crossref","unstructured":"Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents and adults, 1999\u20132002. JAMA.\u20082004;291:2847\u20132850","DOI":"10.1001\/jama.291.23.2847"},{"key":"2021120901594179500_R3","doi-asserted-by":"crossref","unstructured":"Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation.\u20082006;113:898\u2013918","DOI":"10.1161\/CIRCULATIONAHA.106.171016"},{"key":"2021120901594179500_R4","unstructured":"National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH publication 98\u20134083. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998"},{"key":"2021120901594179500_R5","doi-asserted-by":"crossref","unstructured":"Lobstein T, Baur L, Uauy R; IASO International Obesity Task Force. Obesity in children and young people: a crisis in public health. Obes Rev.\u20082004;5(suppl 1):S4\u2013S104","DOI":"10.1111\/j.1467-789X.2004.00133.x"},{"key":"2021120901594179500_R6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics.\u20082000;105:671\u2013680","DOI":"10.1542\/peds.105.3.671"},{"key":"2021120901594179500_R7","doi-asserted-by":"crossref","unstructured":"Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics.\u20081998;102(3). Available at: www.pediatrics.org\/cgi\/content\/full\/102\/3\/e29","DOI":"10.1542\/peds.102.3.e29"},{"key":"2021120901594179500_R8","doi-asserted-by":"crossref","unstructured":"Friberg P, Allansdotter-Johnsson A, Ambring A, et al. Increased left ventricular mass in obese adolescents. Eur Heart J.\u20082004;25:987\u2013992","DOI":"10.1016\/j.ehj.2004.03.018"},{"key":"2021120901594179500_R9","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser.\u20082000;894:i\u2013xii, 1\u2013253"},{"key":"2021120901594179500_R10","doi-asserted-by":"crossref","unstructured":"Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA.\u20081990;264:2519\u20132523","DOI":"10.1001\/jama.264.19.2519"},{"key":"2021120901594179500_R11","doi-asserted-by":"crossref","unstructured":"Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol.\u20081994;13:373\u2013383","DOI":"10.1037\/0278-6133.13.5.373"},{"key":"2021120901594179500_R12","doi-asserted-by":"crossref","unstructured":"Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord.\u20081999;23(suppl 2):S2\u2013S11.","DOI":"10.1038\/sj.ijo.0800852"},{"key":"2021120901594179500_R13","doi-asserted-by":"crossref","unstructured":"Wilson P, O'Meara S, Summerbell C, Kelly S; Effective Health Care Review Team. The prevention and treatment of childhood obesity. Qual Saf Health Care.\u20082003;12:65\u201374","DOI":"10.1136\/qhc.12.1.65"},{"key":"2021120901594179500_R14","unstructured":"Xenical (orlistat) [US product information]. Nutley, NJ: Roche Pharmaceuticals; 2007"},{"key":"2021120901594179500_R15","doi-asserted-by":"crossref","unstructured":"Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res.\u20081999;7:189\u2013198","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"2021120901594179500_R16","doi-asserted-by":"crossref","unstructured":"James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet.\u20082000;356:2119\u20132125","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"2021120901594179500_R17","doi-asserted-by":"crossref","unstructured":"Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med.\u20081999;106:179\u2013184","DOI":"10.1016\/S0002-9343(98)00411-2"},{"key":"2021120901594179500_R18","doi-asserted-by":"crossref","unstructured":"Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord.\u20082002;26(suppl 4):S38\u2013S41.","DOI":"10.1038\/sj.ijo.0802218"},{"key":"2021120901594179500_R19","doi-asserted-by":"crossref","unstructured":"Jordan J, Scholze J, Matiba B, Wirth W, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord.\u20082005;29:509\u2013516","DOI":"10.1038\/sj.ijo.0802887"},{"key":"2021120901594179500_R20","doi-asserted-by":"crossref","unstructured":"Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Int Med.\u20082006;145:81\u201390","DOI":"10.7326\/0003-4819-145-2-200607180-00005"},{"key":"2021120901594179500_R21","doi-asserted-by":"crossref","unstructured":"Rosner B, Prineas R, Loggie J, Daniels S. Percentiles for body mass index in U.S. children 5 to 17 years of age. J Pediatr.\u20081998;132:211\u2013222","DOI":"10.1016\/S0022-3476(98)70434-2"},{"key":"2021120901594179500_R22","unstructured":"Meridia (sibutramine hydrochloride) [package insert]. North Chicago, IL: Abbott Laboratories; 2006"},{"key":"2021120901594179500_R23","doi-asserted-by":"crossref","unstructured":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics.\u20082004;114:555\u2013576","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"2021120901594179500_R24","doi-asserted-by":"crossref","unstructured":"Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA.\u20082003;289:1805\u20131812","DOI":"10.1001\/jama.289.14.1805"},{"key":"2021120901594179500_R25","doi-asserted-by":"crossref","unstructured":"Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab.\u20082005;90:1460\u20131465","DOI":"10.1210\/jc.2004-0263"},{"key":"2021120901594179500_R26","doi-asserted-by":"crossref","unstructured":"Garci\u0301a-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alva\u0301rez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled parallel group trial. Clin Therap.\u20082006;28:770\u2013782","DOI":"10.1016\/j.clinthera.2006.05.008"},{"key":"2021120901594179500_R27","doi-asserted-by":"crossref","unstructured":"Sorof JM, Poffenbarger T, Franco K, Bernard L, Portman RJ. Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr.\u20082002;140:660\u2013666","DOI":"10.1067\/mpd.2002.125228"},{"key":"2021120901594179500_R28","doi-asserted-by":"crossref","unstructured":"Lurbe E, Thijs L, Redon J, Alvarez V, Tacons J, Staessen J. Diurnal blood pressure curve in children and adolescents. J Hypertens.\u20081996;14:41\u201346","DOI":"10.1097\/00004872-199601000-00005"},{"key":"2021120901594179500_R29","doi-asserted-by":"crossref","unstructured":"Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther.\u20082006;79:500\u2013508","DOI":"10.1016\/j.clpt.2006.02.002"},{"key":"2021120901594179500_R30","doi-asserted-by":"crossref","unstructured":"Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med.\u20081992;327:1350\u20131355","DOI":"10.1056\/NEJM199211053271904"},{"key":"2021120901594179500_R31","doi-asserted-by":"crossref","unstructured":"Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey Smith G. Childhood obesity and adult cardiovascular mortality: a 57-y follow-up study based on the Boyd Orr cohort. Am J Clin Nutr.\u20081998;67:1111\u20131118","DOI":"10.1093\/ajcn\/67.6.1111"},{"key":"2021120901594179500_R32","doi-asserted-by":"crossref","unstructured":"Nieto FJ, Szklo M, Comstock GW. Childhood weight and growth rate as predictors of adult mortality. Am J Epidemiol.\u20081992;136:201\u2013213","DOI":"10.1093\/oxfordjournals.aje.a116486"},{"key":"2021120901594179500_R33","doi-asserted-by":"crossref","unstructured":"Srinivasan SR, Bao W, Wattigney WA, Berenson GS. Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study. Metabolism.\u20081996;45:235\u2013240","DOI":"10.1016\/S0026-0495(96)90060-8"},{"key":"2021120901594179500_R34","doi-asserted-by":"crossref","unstructured":"Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics.\u20081999;103:1175\u20131182","DOI":"10.1542\/peds.103.6.1175"},{"key":"2021120901594179500_R35","doi-asserted-by":"crossref","unstructured":"Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med.\u20081998;338:1650\u20131656","DOI":"10.1056\/NEJM199806043382302"},{"key":"2021120901594179500_R36","doi-asserted-by":"crossref","unstructured":"Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988\u20131994. Arch Pediatr Adolesc Med.\u20082003;157:821\u2013827","DOI":"10.1001\/archpedi.157.8.821"},{"key":"2021120901594179500_R37","doi-asserted-by":"crossref","unstructured":"Yanovski JA, Yanovski SZ. Treatment of pediatric and adolescent obesity. JAMA.\u20082003;289:1851\u20131853","DOI":"10.1001\/jama.289.14.1851"},{"key":"2021120901594179500_R38","unstructured":"National Heart, Lung, and Blood Institute, Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health [published correction appears in Obes Res. 1998;6:464]. Obes Res.\u20081998;6(suppl 2):51S\u2013209S"},{"key":"2021120901594179500_R39","doi-asserted-by":"crossref","unstructured":"Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med.\u20082001;344:1343\u20131350","DOI":"10.1056\/NEJM200105033441801"},{"key":"2021120901594179500_R40","doi-asserted-by":"crossref","unstructured":"Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40\u201364 years. Am J Epidemiol.\u20081995;141:1128\u20131141","DOI":"10.1093\/oxfordjournals.aje.a117386"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/e147\/1120109\/zpe0070700e147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/e147\/1120109\/zpe0070700e147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:43:12Z","timestamp":1639039392000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/1\/e147\/70567\/Cardiovascular-Effects-of-Sibutramine-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,7,1]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2137","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}